Annie Mais

Ms. Annie Mais

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2022 in Allergy
Verified
Journal Article
Closed access
PDF file
ETEfthymia Theofani
Efthymia Theofani
MSMaria Semitekolou
Maria Semitekolou
KSKonstantinos Samitas
Konstantinos Samitas
AMAnnie Mais
Annie Mais
IGIoanna E. Galani
Ioanna E. Galani
Georgina XanthouGeorgina Xanthou
Georgina Xanthou

13 August 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
PEPetros Eliadis
Petros Eliadis
AMAnnie Mais
Annie Mais
APAlexandros Papazisis
Alexandros Papazisis
ELEleni K. Loxa
Eleni K. Loxa
ADAlexios Dimitriadis
Alexios Dimitriadis
PLPeggy Lymberi
Peggy Lymberi
Since the initiation of the COVID-19 pandemic, there has been a need for the development of diagnostic methods to determine the factors implicated in mounting an immune response against the virus. The most promising indicator has been suggested to be neutralizing antibodies (nAbs), which mainly block the interaction between the Spike protein (S) of SARS-CoV-2 and the host entry receptor ACE2. In this study, we aimed to develop and optimize conditions of a competitive ELISA to measure serum neutralizing titer, using a recombinant trimeric Spike protein modified to have six additional proline residues (S(6P)-HexaPro) and h-ACE2. The results of our surrogate Virus Neutralizing Assay (sVNA) were compared against the commercial sVNT (cPass, Nanjing GenScript Biotech Co., Nanjing City, China), using serially diluted sera from vaccinees, and a high correlation of ID50–90 titer values was observed between the two assays. Interestingly, when we tested and compared the neutralizing activity of sera from eleven fully vaccinated individuals who subsequently contracted COVID-19 (hybrid sera), we recorded a moderate correlation between the two assays, while higher sera neutralizing titers were measured with sVNA. Our data indicated that the sVNA, as a more biologically relevant model assay that paired the trimeric S(6P) with ACE2, instead of the isolated RBD-ACE2 pairing cPass test, could identify nAbs other than the RBD-RBM specific ones.